Welcome to our dedicated page for BridgeBio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BridgeBio Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BridgeBio Pharma's regulatory disclosures and financial reporting.
BridgeBio Pharma, Inc. (BBIO) reported an insider equity transaction by its Chief Accounting Officer on a Form 4. On 11/16/2025, the officer had 4,781 shares of common stock withheld, coded as transaction type "F," at a price of $66.39 per share. This withholding was used to cover tax obligations tied to the vesting of 9,410 shares of common stock underlying restricted stock units.
After this tax withholding, the reporting person beneficially owns 132,297 shares of BridgeBio Pharma common stock in direct ownership. The filing notes that the transaction relates to routine equity compensation vesting and associated tax settlement, rather than an open-market purchase or sale.
BridgeBio Pharma (BBIO) insider filed a Form 4 reporting open‑market sales totaling 80,000 shares of common stock on 11/06/2025 and 11/07/2025, executed under a Rule 10b5-1 trading plan adopted on March 31, 2025.
Sales were made through trusts where the reporting person is a co‑trustee at weighted average prices within disclosed ranges, with individual trades priced from $60.57 to $64.39 per share. Following these transactions, beneficial holdings reported include 4,598,447 shares (Revocable Trust), 795,686 shares (Family Irrevocable Trust), and 223,090 shares held directly.
BridgeBio Pharma (BBIO) disclosed an insider transaction by a director on 11/06/2025. The director exercised 61,031 stock options at $34.65 per share (code M), receiving shares that same day, and then sold 61,031 shares at a $63.7217 weighted average, within a $63.70–$63.88 range.
Following these trades, the director beneficially owned 16,991 common shares directly and 30,523 options remaining, which expire on 02/11/2030. The option grant vested in three annual installments from February 12, 2020 to February 12, 2023.
BridgeBio Pharma (BBIO): Director insider sales reported. On 10/29/2025, a director reported multiple open‑market sales by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 under a Rule 10b5‑1 plan adopted on August 28, 2024. Transactions included blocks of 111,755 and 43,393 shares, among others, at weighted average prices ranging from $65.4764 to $69.2358. Following the reported sales, 679,979 shares were beneficially owned indirectly by the trust.
BridgeBio Pharma (BBIO): Director transaction reported. A director executed a Rule 10b5-1 planned sale of 1,641 shares of common stock on 10/27/2025 at $65 per share. Following the sale, reported beneficial ownership stands at 878,338 shares held indirectly by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 and 83,275 shares held directly. The 10b5-1 plan was adopted on August 28, 2024.
BridgeBio Pharma (BBIO) reported Q3 2025 results as it scales commercialization of acoramidis (Attruby/Beyonttra). Total revenues were $120.7 million, driven by net product revenue $108.1 million, plus license and services revenue of $8.3 million and royalty revenue of $4.3 million. Loss from operations was $145.2 million. Net loss attributable to common stockholders was $182.7 million (basic and diluted net loss per share $0.95).
Operating expenses reflected launch build-out: research and development was $112.9 million, selling, general and administrative was $137.6 million, and restructuring, impairment and related charges were $8.8 million. Cash and cash equivalents were $642.9 million as of September 30, 2025. The balance sheet shows 2031 Notes, net, of $564.1 million, 2029 Notes, net, of $740.4 million, and 2027 Notes, net, of $546.5 million. Deferred royalty obligations, net, were $836.1 million.
Year-to-date, total revenues were $347.9 million with product revenue of $216.4 million. U.S. accounted for 89.6% of Q3 revenues. The company notes approvals for acoramidis across the U.S., EU, Japan and the UK supporting the commercial ramp.
BridgeBio Pharma, Inc. reported that it issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1.” The disclosure was made in connection with a current report and the press release is attached as Exhibit 99.1.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol BBIO. The report is dated October 29, 2025 and was signed by the President and Chief Financial Officer. Investors can refer to Exhibit 99.1 for the full press release text.
BridgeBio Pharma, Inc. furnished a press release reporting recent business updates and financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 to an Item 2.02 Form 8-K dated October 29, 2025. The company noted that the information in Item 2.02, including Exhibit 99.1, is being furnished and not filed under the Exchange Act.
BridgeBio Pharma (BBIO) filed a Form 8-K announcing it issued a press release titled “BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study.” The press release is furnished as Exhibit 99.1 and is incorporated by reference. This 8-K provides notice of the clinical update; detailed results are contained in the attached exhibit.
BridgeBio Pharma LLC, together with BridgeBio Pharma, Inc., reported acquiring 784,720 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) common stock on 10/10/2025 under transaction code J.
The shares were issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025, in exchange for additional financial and accounting support services provided through December 31, 2025.
After the transaction, 14,589,846 shares were beneficially owned. The shares are held by BridgeBio Pharma LLC, with voting and investment power exercised by its parent, BridgeBio Pharma, Inc. The reporting persons and directors disclaim beneficial ownership except to any pecuniary interest. The reporting person is identified as a director, and the form was filed by more than one reporting person.